Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) traded down 3.8% during trading on Monday . The company traded as low as $2.76 and last traded at $2.77, with a volume of 249,316 shares trading hands. The stock had previously closed at $2.88.

A number of analysts have recently commented on the company. FBR & Co lifted their price target on BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, May 4th. Janney Montgomery Scott reissued a “hold” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. Zacks Investment Research lowered BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a research note on Friday, May 6th. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Finally, Piper Jaffray Cos. reaffirmed a “sell” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $8.25.

The firm’s market capitalization is $150.19 million. The firm has a 50 day moving average price of $2.53 and a 200 day moving average price of $2.94.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). During the same quarter in the prior year, the company earned ($0.37) earnings per share. The business earned $5 million during the quarter, compared to the consensus estimate of $3.35 million. BioDelivery Sciences International’s revenue was up 194.1% compared to the same quarter last year. Analysts anticipate that BioDelivery Sciences International Inc. will post ($1.14) EPS for the current year.

In other BioDelivery Sciences International news, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the transaction, the director now directly owns 122,675 shares in the company, valued at approximately $315,274.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.